CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients

Pediatric Transplantation

Volumn 18, Issue 2, 2014, Pages 166-176

  Xue, Feng ^a   Han, Longzhi ^a   Chen, Yikuan ^a   Xi, Zhifeng ^a   Li, Qigen ^a   Xu, Ning ^a   Xia, Yun ^a   Streicher, Katie ^b   Zhang, Jianjun ^a   Xia, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEDIMMUNE   (United States)

Author keywords

CYP3A5; immune response; pediatric; pharmacokinetics; tacrolimus

Indexed keywords

CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

BACTERIAL INFECTION; CHINA; COMPLICATION; FEMALE; GENETICS; GENOTYPE; HUMAN; INFANT; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PHARMACOGENETICS; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; REGRESSION ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; VIRUS INFECTION;

BACTERIAL INFECTIONS; CHILD, PRESCHOOL; CHINA; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PHARMACOGENETICS; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84893846322     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12216     Document Type: Article

References (29)

1. Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C,. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: Systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010: 66: 1177-1187. Review.
2. Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V,. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005: 9: 162-169. (Pubitemid 40476842)
3. Kausman JY, Patel B, Marks SD,. Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant 2008: 12: 329-335. (Pubitemid 351589446)
4. Ferraris JR, Argibay PF, Costa L, et al. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: Age dependency and pharmacological interaction with steroids. Pediatr Transplant 2011: 15: 525-532.
5. Gijsen V, Mital S, van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant 2011: 30: 1352-1359.
6. Iwasaki K,. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007: 22: 328-335. Review.
7. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001: 27: 383-391. (Pubitemid 32268418)
8. MacPhee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose- normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005: 79: 499-502. (Pubitemid 40280186)
9. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004: 4: 914-919. (Pubitemid 38745590)
10. Min SI, Kim SY, Ahn SH, et al. CYP3A5*1 allele: Impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 2010: 90: 1394-1400.
11. Cho JH, Yoon YD, Park JY, et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 2012: 44: 109-114.
12. Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN,. Tacrolimus-induced nephrotoxicity and genetic variability: A review. Ann Transplant 2012: 17: 111-121. Review.
13. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008: 18: 413-423. (Pubitemid 351535942)
14. Muraki Y, Usui M, Isaji S, et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann Transplant 2011: 16: 55-62.
15. Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006: 12: 775-780.
16. Li L, Li CJ, Zheng L, et al. Tacrolimus dosing in Chinese renal transplant recipients: A population-based pharmacogenetics study. Eur J Clin Pharmacol 2011: 67: 787-795.
17. Xue F, Zhang J, Han L, et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation 2010: 89: 620-626.
18. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006: 82: 663-668. (Pubitemid 44395237)
19. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K,. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006: 16: 119-127. (Pubitemid 43145680)
20. Tang XY, Xia Q, Zhang JJ, et al. Metabolic characteristics and usage of tacrolimus in patients subject to living-donor partial liver transplantation. Chin J Organ Transplant 2010: 31: 749-752.
21. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006: 80: 331-345. (Pubitemid 44479749)
22. Blake MJ, Castro L, Leeder JS, Kearns GL,. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005: 10: 123-138. Review. (Pubitemid 40215540)
23. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE,. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003: 349: 1157-1167. Review. (Pubitemid 37122329)
24. Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: A population pharmacokinetic analysis. Pharmacogenet Genomics 2013: 23: 251-261.
25. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008: 18: 339-348. (Pubitemid 351367527)
26. Satoh S, Saito M, Inoue T, et al. CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol 2009: 65: 473-481.
27. Alak AM, Moy S,. Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. Transplant Proc 1997: 29: 2487-2490. (Pubitemid 27373799)
28. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y,. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010: 32: 394-404.
29. Mizuno S, Hamada T, Nakatani K, et al. Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: Impact of combination assays of immune function and CYP3A5 genotype. J Hepatobiliary Pancreat Sci 2011: 18: 226-232; discussion 232-4.